GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Net Income (Discontinued Operations)

NurExone Biologic (TSXV:NRX) Net Income (Discontinued Operations) : C$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. NurExone Biologic's Net Income (Discontinued Operations) for the three months ended in Dec. 2024 was C$0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

NurExone Biologic Net Income (Discontinued Operations) Historical Data

The historical data trend for NurExone Biologic's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Net Income (Discontinued Operations) Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Income (Discontinued Operations)
- - - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NurExone Biologic Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
TSXV:SHRX TSX:MBX XCNQ:DTC TSX:SVA TSXV:MIR TSX:HBP XCNQ:ONCO TSXV:COV TSX:ONC TSXV:TTI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
NRXBF:USA J90:Germany
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
Website
https://www.nurexone.com
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines